<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="epcor-rdhaxc-rice-maic-darrah">
    <meta name="study:title" content="PS1968 - Match-adjusted comparative analysis of Epcoritamab + R-DHAX/C or R-ICE vs R-DHAX/C or R-ICE in 2L+ transplant-eligible patients with diffuse large B-cell lymphoma">
    <meta name="study:fileName" content="Abstracts/EPCOR-RDHAXC-RICE-MAIC-DARRAH-PS1968.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="2L+">
    <meta name="study:evidenceType" content="Clinical trial"> <meta name="study:drugs" content="Epcoritamab,Bispecific antibodies,Rituximab,Monoclonal Antibody,Dexamethasone,Cytarabine,Oxaliplatin,Carboplatin,Ifosfamide,Etoposide,Chemotherapy,CIT,R-DHAX/C,R-ICE">

    <title>PS1968: Epcoritamab + CIT MAIC in R/R DLBCL (Darrah) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css"> </head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PS1968 - Epcoritamab + R-DHAX/C or R-ICE vs CIT Alone in R/R DLBCL (MAIC)</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996 2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848-.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim</h4>
                    <p>R/R DLBCL Pts (2L+, transplant-eligible). Aim: Contextualize benefit of Epcor + CIT vs CIT alone via MAIC (EPCORE NHL-2 vs COTA).</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention & Comparison</h4>
                    <p>Epcor + R-DHAX/C or R-ICE (N=63, EPCORE NHL-2) vs R-DHAX/C or R-ICE alone (N=48, COTA). IPTW for balancing.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M3.75 3A.75.75 0 003 3.75v16.5a.75.75 0 00.75.75h16.5a.75.75 0 00.75-.75V3.75a.75.75 0 00-.75-.75H3.75zm14.25 1.5H6v13.5h12V4.5zm-10.5 3a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5H9a.75.75 0 000-1.5H6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (Epcor+CIT vs CIT, MAIC)</h4>
                    <p>CR: <span class="highlight-value">62.8% vs 21.4%</span> (RR 2.94, P<0.001). ORR: 82.0% vs 57.4% (RR 1.43, P=0.011). PFS HR 0.17, OS HR 0.08 (both P<0.001).</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Conclusion</h4>
                    <p>Adding Epcor to R-DHAX/C or R-ICE significantly ↑CR rate (2.9-fold) & improves survival in transplant-eligible R/R DLBCL.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PS1968 - Match-adjusted comparative analysis of Epcoritamab + R-DHAX/C or R-ICE vs R-DHAX/C or R-ICE in 2L+ transplant-eligible patients with diffuse large B-cell lymphoma</h1>
            <p class="abstract-sub-header">Justin Darrah, Ke Yang, Tongsheng Wang, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PS1968 | Poster Presentation</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Subcutaneous epcoritamab (epcor), a CD3xCD20 T-cell engaging bispecific antibody, shows sustained efficacy and manageable safety in highly refractory B-cell lymphomas.</li>
                        <li>In R/R transplant-eligible DLBCL, epcor + salvage CIT (R-DHAX/C or R-ICE) in EPCORE NHL-2 (Arms 4 & 10) showed high response rates, enabling most pts to proceed to ASCT in the 2L+ setting.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To contextualize the benefit of adding epcoritamab to R-DHAX/C or R-ICE versus these CIT regimens alone in R/R DLBCL patients intended for transplant, in the absence of head-to-head trial data, using a match-adjusted indirect comparison (MAIC).</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Data Sources:
                            <ul class="list-circle list-inside ml-4">
                                <li>Epcor + R-DHAX/C or R-ICE: Individual patient data (IPD) from Arms 4 & 10 of EPCORE NHL-2 (N=63). Data cutoffs: Arm 4 (Jan 2024), Arm 10 (Dec 2024).</li>
                                <li>R-DHAX/C or R-ICE alone: IPD from COTA database (N=48). Observation period: Jan 2010 - Sep 2024.</li>
                            </ul>
                        </li>
                        <li>Statistical Method: Inverse Probability of Treatment Weighting (IPTW) to balance cohorts across key baseline characteristics (age, gender, ECOG PS, COO, LDH, BM involvement, primary refractory status).</li>
                        <li>Outcomes: CR rate, ORR, PFS, OS. Subgroup analysis for 2L setting.</li>
                        <li>Analysis Models: Weighted log-binomial regression (for RR) and Cox regression models (for HR).</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">MAIC: Epcor+CIT vs CIT Alone in R/R DLBCL</h3>
                        <div class="schema-enrollment">
                            <strong>Patient Data Sources</strong>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group justify-around">
                            <div class="schema-phase cohort-a" style="flex-basis: 48%;">
                                <strong>EPCORE NHL-2 (Arms 4 & 10)</strong>
                                <span>Epcor + R-DHAX/C or R-ICE (N=63)</span>
                            </div>
                             <div class="schema-phase cohort-b" style="flex-basis: 48%;">
                                <strong>COTA Database (RWE)</strong>
                                <span>R-DHAX/C or R-ICE alone (N=48)</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                             <div class="schema-phase" style="flex-basis: 100%; background-color: var(--sobi-light-gray-bg); border-color: var(--sobi-dark-blue);">
                                <strong>Match-Adjusted Indirect Comparison (MAIC)</strong>
                                <span>IPTW to balance baseline characteristics</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-assessment-points">
                           <span>Compare CR, ORR (Adjusted RR)</span>
                           <span>Compare PFS, OS (Adjusted HR)</span>
                           <span>Subgroup Analysis: 2L setting</span>
                        </div>
                    </div>
                </div>
            </div> <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Baseline Characteristics (Pre-Adjustment)</h2>
                    <p class="text-sm mb-2">Compared to CIT alone (N=48), Epcor+CIT (N=63) had more pts aged ≥65 (30.2% vs 25.0%), males (68.3% vs 56.3%), GCB subtype (50.8% vs 27.1%), Stage III/IV (69.8% vs 64.6%), and lower primary refractory status (57.1% vs 81.3%). ECOG PS 1-2 comparable (58.7% vs 62.5%). Cohorts were balanced after match-adjustment.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results (Match-Adjusted Comparison)</h2>
                    <p class="text-sm mb-1">Median follow-up: Epcor+CIT 12.4 mo; CIT alone 9.3 mo.</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li><strong>Complete Response (CR) Rate:</strong>
                            <ul class="list-circle list-inside ml-4">
                                <li>Epcor + CIT: 62.8% (95% CI: 50.9-74.6)</li>
                                <li>CIT alone: 21.4% (95% CI: 9.6-33.1)</li>
                                <li>Relative Risk (RR): 2.94 (P&lt;0.001)</li>
                            </ul>
                        </li>
                        <li><strong>Overall Response Rate (ORR):</strong>
                             <ul class="list-circle list-inside ml-4">
                                <li>Epcor + CIT: 82.0% (95% CI: 72.6-91.4)</li>
                                <li>CIT alone: 57.4% (95% CI: 43.2-71.6)</li>
                                <li>Relative Risk (RR): 1.43 (P=0.011)</li>
                            </ul>
                        </li>
                    </ul>
                     <div class="chart-container my-4">
                        <svg id="epcorCitMaicResponseChart" width="400" height="300"></svg>
                        <div id="epcorCitMaicResponseLegend" class="legend"></div>
                    </div>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mt-3">
                        <li><strong>Progression-Free Survival (PFS):</strong>
                            <ul class="list-circle list-inside ml-4">
                                <li>Epcor + CIT showed 83% reduction in risk of disease progression event.</li>
                                <li>Hazard Ratio (HR): 0.17 (95% CI: 0.09-0.32; P&lt;0.001).</li>
                            </ul>
                        </li>
                        <li><strong>Overall Survival (OS):</strong>
                             <ul class="list-circle list-inside ml-4">
                                <li>Epcor + CIT showed 92% reduction in risk of mortality.</li>
                                <li>Hazard Ratio (HR): 0.08 (95% CI: 0.03-0.19; P&lt;0.001).</li>
                            </ul>
                        </li>
                        <li>Consistent findings observed in subgroup analysis of pts with only 1 prior systemic therapy.</li>
                    </ul>
                </div>
            </div> </div> <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>This match-adjusted indirect comparison suggests that adding epcoritamab to salvage chemoimmunotherapy (R-DHAX/C or R-ICE) provides a significant 2.9-fold increase in the proportion of complete responders eligible for consolidation.</li>
                <li>Furthermore, Epcoritamab + CIT demonstrated significant improvements in survival outcomes (PFS and OS) compared to CIT alone in transplant-eligible R/R DLBCL patients.</li>
                <li>These findings support the potential of Epcoritamab + CIT to optimize salvage therapy for this patient population.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>2L+, Second-line plus; Ab, Antibody; ASCT, Autologous Stem Cell Transplant; BM, Bone Marrow; CI, Confidence Interval; CIT, Chemoimmunotherapy; COO, Cell-of-Origin; COTA, Cancer Outcomes Tracking and Analysis; CR, Complete Response; DLBCL, Diffuse Large B-Cell Lymphoma; ECOG PS, Eastern Cooperative Oncology Group Performance Status; Epcor, Epcoritamab; GCB, Germinal-Center B-cell like; HR, Hazard Ratio; IPD, Individual Patient Data; IPTW, Inverse Probability of Treatment Weighting; LDH, Lactate Dehydrogenase; LOT, Lines of Therapy; MAIC, Match-Adjusted Indirect Comparison; mo, Months; ORR, Overall Response Rate; OS, Overall Survival; PFS, Progression-Free Survival; Pts, Patients; Q, Quartile; R-DHAX/C, Rituximab, Dexamethasone, Cytarabine, Oxaliplatin or Carboplatin; R-ICE, Rituximab, Ifosfamide, Carboplatin, Etoposide; RR, Relative Risk (for response rates); R/R, Relapsed/Refractory; RWE, Real-World Evidence.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Darrah J, Yang K, Wang T, et al. Match-adjusted comparative analysis of Epcoritamab + R-DHAX/C or R-ICE vs R-DHAX/C or R-ICE in 2L+ transplant-eligible patients with diffuse large B-cell lymphoma. Abstract #PS1968 presented at European Haematology Association (EHA) June 12–15, 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PS1968 | Abstract Release: 05/14/25 | Presentation: 06/14/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div> <script defer src="abstract_features.js"></script>
    <script>
    function drawEpcorCitMaicResponseChart(containerId, legendContainerId) {
        const chartTitle = "Response Rates: Epcor+CIT vs CIT Alone (MAIC)";
        // Data: CR: 62.8% vs 21.4%; ORR: 82.0% vs 57.4%
        const chartData = [
            { group: "Epcor + CIT", CR_Rate: 62.8, ORR: 82.0 },
            { group: "CIT Alone", CR_Rate: 21.4, ORR: 57.4 }
        ];
        const subgroups = ["CR_Rate", "ORR"]; // CR Rate will be teal, ORR will be orange
        const displayLabels = {
            "CR_Rate": "CR Rate (%)",
            "ORR": "ORR (%)"
        };
        const units = "%";

        const svg = d3.select(containerId);
        const legendContainer = d3.select(legendContainerId);
        svg.selectAll("*").remove();
        legendContainer.selectAll("*").remove();

        let containerWidth = 400;
        const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
        if (chartWrapper) {
            containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.95, 300);
        }
        
        const svgWidth = containerWidth;
        const svgHeight = +svg.attr("height");
        const margin = { top: 60, right: 20, bottom: 70, left: 60 };
        const chartWidth = svgWidth - margin.left - margin.right;
        const chartHeight = svgHeight - margin.top - margin.bottom;

        if (chartWidth <= 0 || chartHeight <=0) return;

        const g = svg.append("g").attr("transform", `translate(${margin.left},${margin.top})`);
        const groups = chartData.map(d => d.group);
        
        const xScaleGroups = d3.scaleBand().domain(groups).range([0, chartWidth]).padding(0.4); // Adjusted padding
        const xScaleSubgroups = d3.scaleBand().domain(subgroups).range([0, xScaleGroups.bandwidth()]).padding(0.1); // Adjusted padding
        
        const yScale = d3.scaleLinear().domain([0, 100]).range([chartHeight, 0]); // Max is 100%

        const color = d3.scaleOrdinal()
            .domain(subgroups)
            .range(["var(--sobi-teal)", "var(--sobi-orange)"]); // CR Rate (Teal), ORR (Orange)

        g.append("g").attr("transform", `translate(0,${chartHeight})`).call(d3.axisBottom(xScaleGroups))
            .selectAll("text").attr("class", "axis-text").style("font-size", "10px").attr("transform", "rotate(-10) translate(-5,0)").style("text-anchor", "end");
        
        g.append("g").call(d3.axisLeft(yScale).ticks(5).tickFormat(d => d + "%"))
            .selectAll("text").attr("class", "axis-text").style("font-size", "10px");
        
        g.append("text").attr("transform", "rotate(-90)").attr("y", 0 - margin.left + 15).attr("x", 0 - (chartHeight / 2))
            .attr("dy", "1em").style("text-anchor", "middle").attr("class", "axis-label").text("Response Rate (%)");

        g.append("g").attr("class", "grid").call(d3.axisLeft(yScale).ticks(5).tickSize(-chartWidth).tickFormat(""))
            .selectAll("line").style("stroke", "var(--sobi-light-gray)").style("stroke-opacity", "0.7");

        const groupBars = g.selectAll(".group-bar").data(chartData).enter().append("g")
            .attr("class", "group-bar").attr("transform", d => `translate(${xScaleGroups(d.group)},0)`);

        groupBars.selectAll("rect")
            .data(d => subgroups.map(key => ({ key: key, value: d[key] })))
            .enter().append("rect")
            .attr("x", d => xScaleSubgroups(d.key)).attr("y", d => yScale(d.value))
            .attr("width", xScaleSubgroups.bandwidth()).attr("height", d => chartHeight - yScale(d.value))
            .attr("fill", d => color(d.key)).attr("rx", 2).attr("ry", 2);

        groupBars.selectAll(".bar-label")
            .data(d => subgroups.map(key => ({ key: key, value: d[key] })))
            .enter().append("text")
            .attr("class", "chart-label")
            .attr("x", d => xScaleSubgroups(d.key) + xScaleSubgroups.bandwidth() / 2)
            .attr("y", d => yScale(d.value) - 4).attr("text-anchor", "middle")
            .style("font-size", "9px").style("fill", "var(--sobi-dark-text)")
            .text(d => `${d.value.toFixed(1)}${units}`);
        
        svg.append("text").attr("x", svgWidth / 2).attr("y", margin.top / 2)
            .attr("text-anchor", "middle").style("font-size", "13px").style("font-weight", "600")
            .style("fill", "var(--sobi-dark-blue)").text(chartTitle);

        const legendData = subgroups.map(key => ({ label: displayLabels[key], color: color(key) }));
        const legendItems = legendContainer.selectAll(".legend-item").data(legendData).enter().append("div").attr("class", "legend-item");
        legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
        legendItems.append("span").text(d => d.label);
    }
    
    function debounce(func, wait) {
        let timeout;
        return function executedFunction(...args) {
            const later = () => { clearTimeout(timeout); func(...args); };
            clearTimeout(timeout);
            timeout = setTimeout(later, wait);
        };
    };

    const debouncedDrawEpcorCitMaicChart = debounce(() => drawEpcorCitMaicResponseChart("#epcorCitMaicResponseChart", "#epcorCitMaicResponseLegend"), 250);
    
    window.addEventListener('resize', debouncedDrawEpcorCitMaicChart);
    document.addEventListener('DOMContentLoaded', debouncedDrawEpcorCitMaicChart);
    if (document.readyState === "complete" || document.readyState === "interactive") {
         setTimeout(debouncedDrawEpcorCitMaicChart, 0); 
    }
    </script>
</body>
</html>
